ABSTRACT
Background Since 2012 fentanyl-involved fatal overdoses have risen from 4% of all fatal overdoses in Connecticut to 82% in 2019. We investigated the geographic and temporal trends in fentanyl-involved deaths in Connecticut during 2009-2019 and examined the relationship of fentanyl-involved deaths and overall trends of opioid overdose deaths.
Methods Data on the dates and locations of accidental/undetermined opioid-involved fatalities that occurred during 2009-2019 were obtained from Connecticut Office of the Chief Medical Examiner. Using a Bayesian space-time binomial model adjusted for demographic covariates, we estimated spatial and temporal trends in the proportion of fentanyl-involved deaths, as well as overall opioid-involved overdose deaths.
Results During 2009-2019, a total of 6,632 opioid-involved overdose deaths were identified. Among these, 3,234 (49%) were fentanyl-involved. The modeled spatial patterns suggested that opioid-involved deaths in northeastern Connecticut had higher probability of being fentanyl-involved, while New Haven and its neighboring towns and the southwestern region of Connecticut, primarily Greenwich, had a lower risk. Model estimates also suggested the geographic patterns of fentanyl-involved deaths gradually overtook the preceding non-fentanyl opioid overdose deaths. The estimated temporal trend showed the probability of fentanyl involvement increased substantially since 2014.
Conclusion Our findings suggest that geographic variation exists in the probability of fentanyl-involved deaths, and areas at heightened risk are identified. Further studies are warranted to explore the factors contributing to the geographic heterogeneity and continuing dispersion of fentanyl-involved fatal overdoses in Connecticut. Such efforts could inform overdose prevention and intervention strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Institutes of Health/National Institute on Drug Abuse DP2-DA049282 and R37DA15612); National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development DP2-HD091799
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research project has been reviewed by the Connecticut OCME and deemed not human subjects research by the Yale University Human Investigations Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding sources: National Institutes of Health/National Institute on Drug Abuse DP2-DA049282 and R37DA15612); National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development DP2-HD091799
Conflict of interest: None declared.
Data and code: Data are available on request.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
